PPPhilip M. Potter

Philip M. Potter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Philip M. Potter has a total of 454 co-authors. Here are the top co-authors by number of shared publications:

  • Carol C. Edwards

    Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105, United States

    23 shared publications
  • Janice L. Hyatt

    Department of Chemical Biology and Therapeutics, ‡Department of Structural Biology, St. Jude Children's Research Hospital , Memphis, Tennessee 38105, United States

    23 shared publications
  • Monika Wierdl

    Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105-2794, USA

    22 shared publications
  • Lyudmila Tsurkan

    Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee

    21 shared publications
  • Christopher L. Morton

    18 shared publications
  • M. Jason Hatfield

    Department of Chemical Biology and Therapeutics , St. Jude Children's Research Hospital , Memphis , Tennessee 38105 , United States

    17 shared publications

Latest Publications

  • Open Access

    Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer

    by P. Jake Slavish, Liying Chi, Mi-Kyung Yun, Lyudmila Tsurkan, Nancy E. Martinez, Barbara Jonchere, Sergio C. Chai, Michele Connelly, M. Brett Waddell, Sourav Das, et al.

    Inhibition of members of the bromodomain and extraterminal (BET) family of proteins has proven a valid strategy for cancer chemotherapy. All BET identified to date contain two bromodomains (BD; BD1 and BD2) that are necessary for recognition of acetylated lysine residues in the N-terminal regions of histones. Chemical matter that targets BET (BETi) also interact via these domains. Molecular and cellular data indicate that BD1 and BD2 have different biological roles depending upon their cellular context, with BD2 particularly associated with cancer. We have therefore pursued the development of BD2-selective molecules both as chemical probes and as potential leads for drug development. Here we report the structure-based generation of a novel series of tetrahydroquinoline analogs that exhibit >50-fold selectivity for BD2 versus BD1. This selective targeting resulted in engagement with BD-containing proteins in cells, resulting in modulation of MYC proteins and downstream targets. These compounds were potent cytotoxins toward numerous pediatric cancer cell lines and were minimally toxic to nontumorigenic cells. In addition, unlike the pan BETi (+)-JQ1, these BD2-selective inhibitors demonstrated no rebound expression effects. Finally, we report a pharmacokinetic-optimized, metabolically stable derivative that induced growth delay in a neuroblastoma xenograft model with minimal toxicity. We conclude that BD2-selective agents are valid candidates for antitumor drug design for pediatric malignancies driven by the MYC oncogene. Significance: This study presents bromodomain-selective BET inhibitors that act as antitumor agents and demonstrates that these molecules have in vivo activity towards neuroblastoma, with essentially no toxicity.


  • Open Access

    Corrigendum: Inhibition of SF3B1 by molecules targeting the spliceosome results in massive aberrant exon skipping

    by Gang Wu, Liying Fan, Michael N. Edmonson, Timothy Shaw, Kristy Boggs, John Easton, Michael C. Rusch, Thomas R. Webb, Jinghui Zhang, Philip M. Potter

    A monthly journal publishing high-quality, peer-reviewed research on all topics related to RNA and its metabolism in all organisms


  • Potent, Irreversible Inhibition of Human Carboxylesterases by Tanshinone Anhydrides Isolated from Salvia miltiorrhiza (“Danshen”)

    by M. Jason Hatfield, Randall J. Binder, Rowan Gannon, Ellie M. Fratt, John Bowling, Philip M. Potter

    The roots of Salvia miltiorrhiza (“Danshen”) have been used in Chinese herbal medicine for centuries for a host of different conditions. While the exact nature of the active components of this material are unknown, large amounts of tanshinones are present in extracts derived from these samples. Recently, the tanshinones have been demonstrated to be potent human carboxylesterase (CE) inhibitors, with the ability to modulate the biological activity of esterified drugs. During the course of these studies, we also identified more active, irreversible inhibitors of these enzymes. We have purified, identified, and synthesized these molecules and confirmed them to be the anhydride derivatives of the tanshinones. These compounds are exceptionally potent inhibitors (Ki < 1 nM) and can inactivate human CEs both in vitro and in cell culture systems and can modulate the metabolism of the esterified drug oseltamivir. Therefore, the coadministration of Danshen extracts with drugs that contain the ester chemotype should be minimized since, not only is transient inhibition of CEs observed with the tanshinones, but also prolonged irreversible inhibition arises via interaction with the anhydrides.


  • Targeting ALK in pediatric RMS does not induce antitumor activity in vivo

    by Monika Wierdl, Lyudmila Tsurkan, Liying Chi, M. Jason Hatfield, Viktor Tollemar, Cori Bradley, Xiang Chen, Chunxu Qu, Philip M. Potter

    The anaplastic lymphoma kinase (ALK) has been demonstrated to be a valid clinical target in diseases such as anaplastic large cell lymphoma and non-small cell lung cancer. Recent studies have indicated that ALK is overexpressed in pediatric rhabdomyosarcoma (RMS) and hence we hypothesized that this kinase may be a suitable candidate for therapeutic intervention in this tumor.


  • Open Access

    Inhibition of SF3B1 by molecules targeting the spliceosome results in massive aberrant exon skipping

    by Gang Wu, Liying Fan, Michael N. Edmonson, Timothy Shaw, Kristy Boggs, John Easton, Michael C. Rusch, Thomas R. Webb, Jinghui Zhang, Philip M. Potter

    The recent identification of compounds that interact with the spliceosome (sudemycins, spliceostatin A, and meayamycin) indicates that these molecules modulate aberrant splicing via SF3B1 inhibition. Through whole transcriptome sequencing, we have demonstrated that treatment of Rh18 cells with sudemycin leads to exon skipping as the predominant aberrant splicing event. This was also observed following reanalysis of published RNA-seq data sets derived from HeLa cells after spliceostatin A exposure. These results are in contrast to previous reports that indicate that intron retention was the major consequence of SF3B1 inhibition. Analysis of the exon junctions up-regulated by these small molecules indicated that these sequences were absent in annotated human genes, suggesting that aberrant splicing events yielded novel RNA transcripts. Interestingly, the length of preferred downstream exons was significantly longer than the skipped exons, although there was no difference between the lengths of introns flanking skipped exons. The reading frame of the aberrantly skipped exons maintained a ratio of 2:1:1, close to that of the cassette exons (3:1:1) present in naturally occurring isoforms, suggesting negative selection by the nonsense-mediated decay (NMD) machinery for out-of-frame transcripts. Accordingly, genes involved in NMD and RNAs encoding proteins involved in the splicing process were enriched in both data sets. Our findings, therefore, further elucidate the mechanisms by which SF3B1 inhibition modulates pre-mRNA splicing.


  • Open Access

    Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma

    by Margarita Gutova, Leanne Goldstein, Marianne Metz, Anahit Hovsepyan, Lyudmila G. Tsurkan, Revathiswari Tirughana, Lusine Tsaturyan, Alexander J. Annala, Timothy W. Synold, Zesheng Wan, et al.


  • Selective Inhibitors of Human Liver Carboxylesterase Based on a β-Lapachone Scaffold: Novel Reagents for Reaction Profiling

    by M. Jason Hatfield, Jingwen Chen, Ellie M. Fratt, Liying Chi, John C. Bollinger, Randall J. Binder, John Bowling, Janice L. Hyatt, Jerrod Scarborough, Cynthia Jeffries, et al.

    Carboxylesterases (CEs) are ubiquitous enzymes that are responsible for the metabolism of xenobiotics, including drugs such as irinotecan and oseltamivir. Inhibition of CEs significantly modulates the efficacy of such agents. We report here that β-lapachone is a potent, reversible CE inhibitor with Ki values in the nanomolar range. A series of amino and phenoxy analogues have been synthesized, and although the former are very poor inhibitors, the latter compounds are highly effective in modulating CE activity. Our data demonstrate that tautomerism of the amino derivatives to the imino forms likely accounts for their loss in biological activity. A series of N-methylated amino derivatives, which are unable to undergo such tautomerism, were equal in potency to the phenoxy analogues and demonstrated selectivity for the liver enzyme hCE1. These specific inhibitors, which are active in cell culture models, will be exceptionally useful reagents for reaction profiling of esterified drugs in complex biological samples.


  • Carboxylesterases: General detoxifying enzymes

    by M. Jason Hatfield, Robyn A. Umans, Janice L. Hyatt, Carol C. Edwards, Monika Wierdl, Lyudmila Tsurkan, Michael R. Taylor, Philip M. Potter


  • Tumour‐selective targeting of drug metabolizing enzymes to treat metastatic cancer

    by Monika Wierdl, Lyudmila Tsurkan, M. Jason Hatfield, Philip M. Potter

    Carboxylesterases (CEs) are ubiquitous enzymes responsible for the detoxification of ester-containing xenobiotics. This hydrolysis reaction results in the formation of the corresponding carboxylic acid and alcohol. Due to their highly plastic active site, CEs can hydrolyze structurally very distinct and complex molecules. Because ester groups significantly increase the water solubility of compounds, they are frequently used in the pharmaceutical industry to make relatively insoluble compounds more bioavailable. By default, this results in CEs playing a major role in the distribution and metabolism of these esterified drugs. However, this can be exploited to selectively improve compound hydrolysis, and using specific in vivo targeting techniques can be employed to generate enhanced drug activity. Here, we seek to detail the human CEs involved in esterified molecule hydrolysis, compare and contrast these with CEs present in small mammals and describe novel methods to improve drug therapy by specific delivery of CEs to cells in vivo. Finally, we will discuss the development of such approaches for their potential application towards malignant disease.